The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of high-risk features on disease-free survival (DFS) in patients (pts) with high-risk stage II colon cancer (CC) in ACHIEVE-2 trial as part of the IDEA collaboration.
 
Dai Manaka
No Relationships to Disclose
 
Manabu Shiozawa
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Makio Gamoh
Honoraria - Asahi Kasei; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sanofi; Shionogi; Taiho Pharmaceutical; Takeda
Travel, Accommodations, Expenses - Ono Pharmaceutical; Shionogi
 
Akio Shiomi
No Relationships to Disclose
 
Akitaka Makiyama
Speakers' Bureau - Chugai Pharma; Lilly; Takeda
 
Yoshinori Munemoto
No Relationships to Disclose
 
Toshiki Rikiyama
No Relationships to Disclose
 
Mutsumi Fukunaga
No Relationships to Disclose
 
Takashi Ueki
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroshi Shinkai
No Relationships to Disclose
 
Nobuyuki Tanida
No Relationships to Disclose
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Eiji Sunami
No Relationships to Disclose
 
Takeharu Yamanaka
Honoraria - Bayer; Boehringer Ingelheim; Chugai Pharma
Consulting or Advisory Role - Gilead Sciences; HUYA Bioscience International; Sysmex
Research Funding - Bayer (Inst); Chugai/Roche (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Chugai Pharma; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb
 
Yoshihiko Maehara
No Relationships to Disclose